The EU Sues AstraZeneca. Why?

Published April 27th, 2021 - 06:57 GMT
COVID-19 vaccine
AstraZeneca vaccine. (Shutterstock/ File Photo)
Highlights
Denmark dropped the AstraZeneca COVID-19 vaccine this month because of a possible link to rare blood clots in recipients.

The European Union announced Monday that it has filed a lawsuit against drugmaker AstraZeneca for failure to deliver its COVID-19 vaccine.

AstraZeneca said early this year it would not be able to deliver on the amount of vaccine doses scheduled for European Union countries over the first three months of 2021.

The European Commission, the executive branch of the European Union, started a legal action against the company on Friday that says Astrazeneca breached its purchase contract. The EC said all 27 European Union members support the legal move.

The European Union's vaccine contract with AstraZeneca covers 400 million doses. The company has so far delivered about 30 million doses, The New York Times reported.


The pharma company denied that it has breached its contract because the EU had placed its order after other countries.

"Following an unprecedented year of scientific discovery, very complex negotiations, and manufacturing challenges, our company is about to deliver almost 50 million doses to European countries by the end of April, in line with our forecast," Astrazeneca said Monday, according to CNN.

"AstraZeneca has fully complied with the advance purchase agreement with the European Commission and will strongly defend itself in court."

Denmark dropped the AstraZeneca COVID-19 vaccine this month because of a possible link to rare blood clots in recipients. Officials said this month that 2.4 million doses of the vaccine would be withdrawn until further notice.

Other countries, including Germany, have restricted the AstraZeneca vaccine to older age groups, who are believed to be at a reduced risk for blood clots.

The vaccine has not been approved for use in the United States.

This article has been adapted from its original source.


Copyright © UPI, 2021. All Rights Reserved.

You may also like

Subscribe

Sign up to our newsletter for exclusive updates and enhanced content